Understand the source comparison
Best Peptides for EBV Reactivation: Research Tool Comparison
Thymosin Alpha-1 TLR9 agonist; upregulates IL-2 and IFN-gamma via dendritic cell activation Increased CD4+ counts (18–22% in HBV trials); enhanced cytotoxic T-cell differentiation Phase III HBV trials (Hepatology 2004); chronic viral infection immunotherapy Fi
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Thymosin Alpha-1
- TLR9 agonist; upregulates IL-2 and IFN-gamma via dendritic cell activation
- Increased CD4+ counts (18–22% in HBV trials); enhanced cytotoxic T-cell differentiation
- Phase III HBV trials (Hepatology 2004); chronic viral infection immunotherapy
- First-line tool for T-cell reconstitution research; strongest evidence base for restoring antiviral surveillance
- Thymalin (Thymulin analog)
- Thymic hormone replacement; restores CD4/CD8 ratios and naïve T-cell output
- 27% increase in CD8+ naïve T-cells (University of Liège aging study); reverses thymic involution markers
- Immunosenescence models; age-related immune decline research
- Best suited for protocols targeting thymic restoration in older populations or post-chemotherapy immune recovery
- BPC-157
- VEGF and NO pathway modulation; mucosal barrier restoration
- Reduced oral mucosal inflammation; indirect reduction in viral shedding sites
- Tissue repair models; gastric and oral mucosa integrity studies
- Supportive rather than primary; addresses mucosal inflammation that permits reactivation shedding but doesn't restore T-cell surveillance
- Selank
- Anxiolytic peptide; modulates IL-6 and reduces cortisol-driven immunosuppression
- Normalized IL-6 levels in chronic stress models; prevented stress-induced NK cell suppression
- Stress-immunity research; glucocorticoid-mediated immune dysfunction
- Relevant only when chronic stress is a documented reactivation trigger; minimal direct antiviral effect
- Epithalon
- Telomerase activator; theoretical T-cell lifespan extension
- Extended T-cell replicative capacity in vitro; unproven in human viral latency models
- Aging research; experimental lifespan extension studies
- Speculative for EBV protocols; no direct evidence of improved latency control; mechanism doesn't address thymic output decline